Characterisation of male breast cancer: a descriptive biomarker study from a large patient series

Humphries, Matthew P.; Rajan, Sreekumar Sundara; Honarpisheh, Hedieh; Cserni, Gábor; Dent, Jo; Fulford, Laura; Jordan, Lee B.; Jones, J. Louise; Kanthan, Rani; Litwiniuk, Maria; Benedetto, Anna Di; Mottolese, Marcella; Provenzano, Elena; Shousha, Sami; Stephens, M. A.; Kulka, Janina; Ellis, Ian O.; Titloye, Akinwale N; Hanby, Andrew M.; Shaaban, Abeer M.; Speirs, Valerie

doi:10.1038/srep45293

Cited by 56 publications

(51 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is of special interest, as AR positivity is being studied in ER-positive disease [20]. This receptor could eventually play role in treatment, as it seems to be a new possible treatment target and thereby both a prognostic and predictive marker [4,21,22].…”

Section: Discussionmentioning

confidence: 99%

Male breast cancer: clinicopathological characterization of a National Danish cohort 1980–2009

et al. 2020

View full text Add to dashboard Cite

Background To describe relevant pathological parameters of Danish male breast cancer patients (MBCP) diagnosed from 1980 to 2009, and to relate these data to treatment, overall survival (OS) and standardized mortality rate (SMR). Materials and methods The MBCP cohort was defined from national Danish registers. A total of 643 MBCP were identified with tissue available in 457. Among these, 384 were primary operable. Where tissue blocks were available, tumor type, grade, estrogen receptor (ER), progesteron receptor (PgR) and androgen-receptor (AR) status as well as HER 2 and Ki67 were performed. OS was quantified by Kaplan-Meier estimates and SMR was calculated based on mortality rate among patients relative to the mortality rate in the general population. Results Male breast cancer was more often of ductal type, grade II and a very high proportion were ER and AR positive and HER2 negative. Intrinsic subtypes based on immunohistochemical evaluation showed luminal subtype. Ki67 ratio increased over period of study. OS declined by increased age, bigger tumor size, positive lymph node status, higher grade and Luminal B subtype. Hazard ratio and relative risk of SMR were highest for patients aged < 60 years. Conclusion Male breast cancer is of luminal subtype, but more often Luminal B. Ki67 is crucial in evaluation of subtypes by immunohistochemistry, but have limitations. Subtyping seems to be of major importance. AR also can have a role in future treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Male breast cancer: clinicopathological characterization of a National Danish cohort 1980–2009

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The most histological subtype is IBC NST of intermediate grade (G2), but papillary, lobular, or mixed growth patterns as well as (rarely) G1 and G3 tumors can occur [116]. Typically, IBC of the male breast harbors ER and/ or PR positivity and HER2 negativity, and matches with luminal A subtype [117].…”

Section: Ibc Of the Male Breastmentioning

confidence: 99%

Histology of Luminal Breast Cancer

Erber

Hartmann²

2020

Breast Care

View full text Add to dashboard Cite

Background: Invasive breast cancer (IBC) can be categorized into prognostic and predictive molecular subtypes (including luminal breast cancer) using gene expression profiling. Luminal IBC comprises a variety of histological subtypes with varying clinical and pathological features. Summary: IBC of no special subtype is the most common histological subtype in general and likewise within luminal IBC. Classical invasive lobular breast cancer, typically clustering into luminal subgroup, is characterized by discohesive growth and loss of E-cadherin expression. Infrequent, morphologically distinct luminal IBC subtypes are tubular, invasive cribriform, mucinous, and invasive micropapillary carcinomas. Breast carcinoma with apocrine differentiation, with characteristic expression of androgen receptor (AR), often clusters into the luminal AR category. Rarely, neuroendocrine neoplasms of the breast can be seen. IBC of the male breast usually matches with the luminal subtype. Key Messages: Independently from histological subtypes, invasive breast cancer (IBC) can be divided into molecular subtypes based on mRNA gene expression levels. Using this molecular subtyping, risk scores based on gene expression profiling (established for hormone receptor-positive, HER2-negative IBC), grading, and Ki-67 index, prognosis of patients with luminal breast cancer and response to chemotherapy can be predicted. In routine diagnostics, the expression of estrogen receptor (ER) and progesterone receptor (PR), HER2 status, and the proliferation rate (Ki-67) are used to determine a surrogate (molecular-like) subtype. Within luminal(-like) IBC, no special sub-type and invasive lobular breast carcinoma are the most common histological subtypes. Other rare histological subtypes (e.g., tubular carcinoma) should be recognized due to their distinct clinical and pathological features.

show abstract

“…There are encouraging signs of international collaborations studying MBC so that there is an improvement in the understanding of the presentation and characterisation of the disease (Humphries et al 2017, Vermeulen et al 2017, Cardoso et al 2018. It is also becoming clearer that obesity and the metabolic results thereof may play an important role in the development of MBC as result of decrease in androgens and increase in oestrogens.…”

Section: Discussionmentioning

confidence: 99%

The endocrinology of male breast cancer

Fentiman¹

2018

Endocrine-Related Cancer

View full text Add to dashboard Cite

Male breast cancer (MBC) is a rare disease but, as a result of epidemiological collaborations, there is now greater clarity concerning endocrine risk factors. The significant rise in global age-standardised mean BMI in men is likely to lead to increases in incidence of maturity-onset diabetes and MBC. The metabolic changes accompanying obesity decrease androgens and sex hormone-binding globulin (SHBG), thereby increasing available oestrogens. The higher rates of MBC in North and Equatorial Africa are largely due to liver damage from endemic bilharziasis and hepatitis B causing elevated oestradiol (E) levels from hepatic conversion of androgen. Klinefelter's syndrome (XXY) is associated with a 50-fold increase in incidence of MBC compared with XY males, and this is the most pronounced evidence for testicular malfunction amplifying risk. Delay in presentation means that up to 40% of cases have stage III or stage IV disease at diagnosis. No randomised controlled trials have been reported on endocrine treatment of advanced disease or adjuvant/neoadjuvant therapy following or preceding surgery. Tamoxifen is the most effective endocrine therapy, but side effects can lead to non-compliance in a substantial number of men. Aromatase inhibitors are less effective because they do not inhibit testicular oestrogen production. There is an urgent need for collaborative trials to provide an evidence base for the most effective endocrine and least toxic therapies for men with breast cancer.

show abstract

Characterisation of male breast cancer: a descriptive biomarker study from a large patient series

Cited by 56 publications

References 47 publications

Male breast cancer: clinicopathological characterization of a National Danish cohort 1980–2009

Male breast cancer: clinicopathological characterization of a National Danish cohort 1980–2009

Histology of Luminal Breast Cancer

The endocrinology of male breast cancer

Contact Info

Product

Resources

About